Dinakaran Damodharan, Sreeraj Vanteemar S, Venkatasubramanian Ganesan
Dept. of Psychiatry, National Institute of Mental Health And Neurosciences (NIMHANS), Bengaluru, Karnataka, India.
Indian J Psychol Med. 2022 Mar;44(2):107-113. doi: 10.1177/02537176211033331. Epub 2021 Sep 13.
Nutraceutical agents and food supplements are commonly used as treatment adjuncts in neuropsychiatric disorders. Curcumin, a bioactive agent obtained from the rhizome of , with its antioxidant and anti-inflammatory properties, has gained much research attention in the last few decades. In this narrative review, we intend to summarize the evidence available for curcumin as an add-on agent in the management of schizophrenia. We searched PubMed/EBSCO for both human and animal trials utilizing curcumin in the management of schizophrenia. We obtained ten articles (five preclinical and five clinical) from the focused literature search. Clinical research utilizing curcumin in schizophrenia is limited to negative and cognitive symptoms. Available preclinical studies suggest curcumin's utility in ameliorating extrapyramidal and metabolic side effects when given as an adjunct with antipsychotics. Curcumin, as an add-on agent, appears promising to improve the negative and cognitive symptoms of schizophrenia. Notably, curcumin was tolerable and safe in all the randomized human clinical trials. The poor oral bioavailability is, however, a limiting factor in its widespread use.
营养保健品和食品补充剂通常被用作神经精神疾病的辅助治疗手段。姜黄素是一种从姜黄根茎中提取的生物活性物质，具有抗氧化和抗炎特性，在过去几十年中受到了广泛的研究关注。在这篇叙述性综述中，我们旨在总结姜黄素作为精神分裂症治疗辅助药物的现有证据。我们在PubMed/EBSCO数据库中检索了使用姜黄素治疗精神分裂症的人体和动物试验。通过重点文献检索，我们获得了10篇文章（5篇临床前研究和5篇临床研究）。在精神分裂症中使用姜黄素的临床研究仅限于阴性症状和认知症状。现有的临床前研究表明，姜黄素与抗精神病药物联合使用时，在改善锥体外系和代谢副作用方面具有一定作用。作为一种辅助药物，姜黄素似乎有望改善精神分裂症的阴性症状和认知症状。值得注意的是，在所有随机人体临床试验中，姜黄素都是可耐受且安全的。然而，口服生物利用度低是其广泛应用的一个限制因素。
